Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 HKD | -2.31% | +11.28% | -30.19% |
04-03 | Alibaba Health Refutes Rumors of Purchase of Telemedicine Platform HaoDF | MT |
03-28 | Alibaba Health Information Technology Limited and Alibaba.com Enter Shared Services Agreement | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 55.91 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.19% | 6.09B | B | ||
-33.40% | 15.3B | B- | ||
-30.56% | 11.07B | B | ||
+9.74% | 6.13B | C | ||
-9.57% | 5.95B | C+ | ||
+0.88% | 4.79B | D- | ||
+53.60% | 4.36B | - | C | |
-10.49% | 3.69B | B | ||
-12.53% | 3.43B | C- | ||
-6.53% | 3.05B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 241 Stock
- Ratings Alibaba Health Information Technology Limited